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Abstract A missense mutation, A843E, in the seventh trans-
membrane domain of the human Ca2+ receptor, identified in a
subject with autosomal dominant hypocalcemia, was found to
cause a constitutive activation while at the same time lowering
the maximal response of the receptor to Ca2+. A truncated
human Ca2+ receptor lacking the majority of the N-terminal
extracellular domain failed to respond to Ca2+ despite an
excellent cell surface expression. The A843E mutant version of
this truncated receptor showed constitutive activation. These
results identify A843 as a critical residue for maintaining the
inactive conformation of the human Ca2+ receptor. Substitution
of glutamate, but not lysine or valine, for alanine 843 leads to
activation of the human Ca2+ receptor in a manner that no longer
depends upon Ca2+ binding to the extracellular domain.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Activating mutations of G protein-coupled receptors
(GPCR) have been identi¢ed as the cause of several human
diseases [1]. Functional expression studies of such mutant re-
ceptors have in general shown that they are constitutively
activated, i.e. they activate G protein in an agonist-independ-
ent manner (for example [2]). Activating mutations have also
been identi¢ed in the human Ca2 receptor (hCaR) in a dis-
order termed autosomal dominant hypocalcemia (ADH) [3].
The CaR is a member of the GPCR gene superfamily that is
expressed at particularly high levels in parathyroid and kidney
where it serves to regulate the extracellular Ca2 metabolism
[4]. Extracellular Ca2 directly activates the CaR causing in-
hibition of parathyroid hormone (PTH) secretion from the
parathyroids and a decreased renal Ca2 reabsorption. Germ-
line heterozygous, activating missense mutations of the hCaR,
cause inhibition of the PTH secretion and a decreased renal
Ca2 reabsorption at an inappropriately low serum Ca2 con-
centration, leading to the hypocalcemia, relative hypercalciu-
ria and an inappropriately low serum PTH that characterizes
subjects with ADH [5].
Functional expression of hCaRs with mutations identi¢ed
in subjects with ADH to date has shown that they are not, in
fact, constitutively activated. Activities of mutant and wild-
type receptors do not di¡er at a very low Ca2 concentration,
but the mutant receptors show an enhanced sensitivity to
Ca2 with an EC50 shifted leftward by a factor of almost
two [3,6^8]. Most mutations identi¢ed in subjects with ADH
are located in the large, V600 residue N-terminal extracellu-
lar domain (ECD) of the hCaR where they might be expected
to in£uence the sensitivity to Ca2 activation, but even the
few mutations identi¢ed within the seven transmembrane por-
tion of the CaR in subjects with ADH have shown a pattern
of increased sensitivity to Ca2 rather than constitutive acti-
vation [7,9].
During the course of our studies on expression of mutant
CaRs, we found that a mutation, alanine 843 to glutamate
(A843E), identi¢ed in the seventh transmembrane domain of
the hCaR in a subject with hypocalcemia and hypercalciuria
[10] causes a true constitutive activation. Substitution of A843
by amino acids other than glutamate did not lead to constit-
utive activation. By constructing a form of the hCaR that
lacked the ECD but still was expressed at the cell surface,
we were able to show that constitutive activation caused by
the A843E mutation does not depend on an intact ECD.
These studies o¡er a new insight into the mechanism of acti-
vation of the hCaR.
2. Materials and methods
2.1. Site-directed mutagenesis
The entire encoding region of the hCaR [11] was subcloned in
pCR3.1 (Invitrogen, San Diego, CA, USA). Site-directed mutagenesis
was carried out by using the QuickChange site-mutagenesis kit (Stra-
tagene, La Jolla, CA, USA). The pairs of oligonucleotide primers used
for each mutation are available on request from the authors. All
mutations were con¢rmed by sequencing using ABI prism dRhod-
amine terminator cycle sequencing ready reaction kit and ABI
prism-377 sequencer (Applied Biosystems, Foster City, CA, USA).
2.2. Construction of N-terminal-truncated hCaR with a rhodopsin
epitope tag (Rho-C-hCaR)
A polymerase chain reaction (PCR) was used to add 20 amino acid
residues (MNGTEGPNFYVPFSNKTGVV) corresponding to the N-
terminus of bovine rhodopsin to the hCaR at residue 599. The sense
primer used was a 100 base oligonucleotide corresponding to the
nucleotide sequence of the N-terminal 20 amino acids of bovine rho-
dopsin and the nucleotide positions 1797^1832 of hCaR cDNA: 5P-
CAGCCATGAACGGGACCGAGGGCCCAAACTTCTACGTGC-
CTTTCTCCAACAAGACGGGCGTGGTGGCCAAGGAGATCG-
AGTTTCTGTCGTGGACGGAGCC-3P. The antisense primer used
was a 46 base oligonucleotide corresponding to the nucleotide posi-
tions 2667^2709 of hCaR cDNA and a stop codon, 5P-CCTAT-
CCAAGGCTGCTGGACCGCTTGCGGGAGACGTTGCTGCGG-
CG-3P. The PCR was done by using the Advantage cDNA PCR kit
(Clontech, Palo Alto, CA, USA). The PCR product was subcloned to
the PCDNA3.1 vector by using the Eukaryotic TA cloning kit (Invi-
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trogen, San Diego, CA, USA). The entire sequence of the PCR prod-
uct was con¢rmed by using the ABI prism dRhodamine terminator
cycle sequencing ready reaction kit and an ABI prism-377 sequencer
(Applied Biosystems, Forster City, CA, USA). The truncated mutant
hCaR, designated Rho-C-hCaR, includes 20 amino acids of the N-
terminus of rhodopsin and the amino acid residues 599^903 of hCaR.
2.3. Transient transfection of wild-type and mutant hCaRs in HEK-293
cells
Transfections were performed as previously described [11]. In brief,
hCaR cDNAs for transfection were prepared by the QIAGEN Maxi
plasmid DNA preparation kit (QIAGEN, Chatsworth, CA, USA).
Lipofectamine (Life Technologies, Gaithersburg, MD, USA) was em-
ployed as the DNA carrier for transfection. The HEK-293 cells used
for transfection were cultured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) with 10% fetal bovine serum (FBS) (BioFluids, Rockville,
MD, USA), 1% glutamine and 1% penicillin/streptomycin. The DNA-
liposome complex was prepared by mixing DNA and Lipofectamine
in DMEM and incubating the mixture for 30 min at room temper-
ature. The DNA-Lipofectamine complex was further diluted in serum-
free DMEM and added to 90% con£uent HEK-293 cells. After 5 h of
incubation, an equal volume of regular medium with 20% FBS was
added and the medium was replaced 24 h after transfection with fresh
medium.
2.4. Phosphoinositide hydrolysis assay
The assay was performed as previously described [12,13]. Brie£y,
HEK-293 cells grown in supplemented DMEM were plated in 24 well
culture plates at 80^90% con£uency. 24 h after being transfected with
wild-type and mutant hCaR, cells were incubated with 3.0 WCi/ml
[3H]myoinositol (New England Nuclear, Boston, MA, USA) in full
medium (DMEM+10% FBS+1% glutamine+1% and 1% penicillin/
streptomycin) for 16^24 h, followed by 30 min preincubation with
PI bu¡er (119 mM NaCl, 5 mM KCl, 5.6 mM glucose, 0.4 mM
MgCl2, 20 mM LiCl in 25 mM PIPES bu¡er, pH 7.2). Cells were
stimulated with various extracellular Ca2 concentrations in PI bu¡er
for 30 min. The reaction was terminated by the addition of 1 ml acid-
methanol (167 Wl HCl in 120 ml methanol). Total [3H]inositol phos-
phates were extracted and separated on Dowex AG1-X8 columns as
described [12,13].
2.5. An intact cell enzyme-linked immunoassay (ELISA) to determine
the cell surface expression of transfected receptors
Transfected HEK-293 cells in six well plates were detached with
1 mM EDTA in PBS containing 0.5% bovine serum albumin. To
measure the cell surface expression of wild-type and mutant CaR
with an intact ECD, cells were incubated in DMEM for 1 h on ice
with 1 Wg/ml monoclonal antibody 7F8 raised against the puri¢ed
ECD of hCaR as previously described [11,14]. The cell surface ex-
pression was calculated as the percentage OD compared with the
value of wild-type hCaR (set as 100%) after subtracting the OD value
of cells transfected with vector alone. To measure the cell surface
expression of receptors with a rhodopsin epitope tag, a monoclonal
antibody against the N-terminus of rhodopsin, B6-30N [15], was used
instead of 7F8.
3. Results
3.1. Analysis of the mutant hCaR signal transduction using a
phosphoinositide hydrolysis assay
The function of wild-type and mutant hCaRs expressed in
transfected HEK-293 cells was assessed by measuring the PI
hydrolysis in response to increasing concentrations of Ca2.
The response of two di¡erent missense mutants identi¢ed in
subjects with ADH, alanine 116 to threonine (A116T) [16] and
A843E [10], was compared in this assay with the wild-type
hCaR (Fig. 1). The A116T mutant, like other activating
hCaR mutations studied to date [3,6,7,9], shows no signi¢cant
di¡erence from the wild-type receptor at very low Ca2 con-
centrations, but its EC50 is shifted leftward V2-fold. The PI
response of the A843E mutant, in contrast, even in the ab-
sence of extracellular Ca2, corresponds to 50^60% of the
maximum response of the wild-type hCaR. The A843E mu-
tant, however, does not reach the same level of activation as
the wild-type receptor even at very high Ca2 concentrations.
The A843E mutant Ca2-independent activation of PI hydrol-
ysis was observed over a range of transfected cDNA from
0.25 to 6 Wg/ml. The PI assay in the absence of Ca2 of cells
transfected over this range with either wild-type or A116T
mutant hCaR cDNAs showed a constant low level of activity.
In contrast, transfection with A843E mutant cDNA increased
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Fig. 1. Concentration-dependence for the Ca2 stimulation of phos-
phoinositide hydrolysis in transiently transfected HEK-293 cells ex-
pressing wild-type and activating mutant (A116T and A843E) hCaR
cDNAs. Each data point is the mean value of triplicate determina-
tions from six independent experiments. All responses are normal-
ized to the maximum response of the wild-type hCaR. The S.E.M.
is marked with a vertical bar through each point.
Fig. 2. Concentration-dependence for the Ca2 stimulation of phos-
phoinositide hydrolysis in transiently transfected HEK-293 cells ex-
pressing the wild-type, A843(E, K or V) and A840E mutant hCaR
cDNAs. The data are expressed as described in the legend to Fig. 1
except that the S.E.M. which was 6 10% is not shown.
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the activity in this assay compared with the wild-type at every
concentration of DNA used, with a peak activity at 1 Wg/ml
DNA (data not shown).
To determine whether constitutive activation caused by the
A843E mutation is due to substitution of A843 or speci¢cally
requires the substitution by glutamate, we created several ad-
dition mutants, substituting A843 with either positively
charged lysine (A843K) or uncharged valine (A843V). We
also made another mutant in which a neighboring alanine in
the seventh transmembrane domain is substituted by gluta-
mate (A840E). Unlike A843E, none of these mutants caused
a constitutive activation, although like A843E, the maximal
activation of all these mutants was only 50^60% of that of the
wild-type (Fig. 2). The PI response of A840E and A843K
mutants demonstrated a leftward shift compared to wild-
type, whereas the A843V mutant showed a rightward shift
compared to wild-type.
3.2. Cell surface expression assessed by an intact cell ELISA
In order to determine if the di¡erences in activity observed
for the mutant hCaRs were due to di¡erences in cell surface
expression, we measured the cell surface expression level with
an ELISA using a monoclonal antibody raised against the
puri¢ed ECD of hCaR. As illustrated in Fig. 3, mutant
hCaRs (A116T, A840E, A843K, A843V) were all expressed
at levels close to that of the wild-type. Failure of the maxi-
mum PI response of mutant hCaRs (A840E, A843K, A843V)
to reach wild-type levels cannot therefore be ascribed to a
reduced cell surface expression. As for the constitutively acti-
vating mutant A843E, its average cell surface expression level
is signi¢cantly lower, corresponding to 85% of the wild-type
expression. Thus, the increased cell surface expression cannot
account for the constitutive activation observed for the A843E
mutant.
3.3. Expression of truncated hCaRs lacking the ECD
We hypothesized that the ability of the A843E mutation to
constitutively activate the hCaR was not dependent on an
intact ECD. To test this hypothesis, we sought to construct
a truncated form of the hCaR lacking the ECD. We have
shown previously that truncation of the long intracellular C-
terminus of the hCaR at residue 903 does not impair receptor
activation or G protein coupling and may enhance the cell
surface expression [11]. We therefore combined the C-terminal
truncation at residue 903 with truncation of the ECD prox-
imal to the ¢rst transmembrane domain to generate mutants
lacking the ECD. We found that such mutants were not ex-
pressed at the cell surface even if we included the hCaR signal
sequence at the N-terminus (data not shown). To circumvent
this problem, we created a mutant (rho-C-hCaR) with the C-
terminal residue 903 truncation combined with a N-terminus
consisting of the ¢rst 20 residues of bovine rhodopsin fol-
lowed by the remainder of the hCaR beginning with residue
599. The N-terminal rhodopsin sequence contains an epitope
for the rhodopsin monoclonal antibody, B6-30N, providing a
convenient means of monitoring the cell surface expression of
rho-C-CaR. Immunoblots showed an excellent expression of
rho-C-CaR (data not shown). We next generated a form of
rho-C-hCaR containing the A843E mutation and compared
the PI hydrolysis response to Ca2 of cells transfected with
rho-C-hCaR, rho-C-hCaR(A843E) and wild-type hCaR
cDNAs. Rho-C-hCaR showed no response to Ca2, whereas
the rho-C-hCaR(A843E) mutant showed constitutive activa-
tion at a level only slightly lower than that of the full length
A843E hCaR mutant (Fig. 4). Failure of the rho-C-hCaR
mutant to respond to Ca2 was not due to a lack of cell
surface expression, since the intact cell ELISA using the rho-
dopsin monoclonal antibody showed that rho-C-hCaR and
rho-C-hCaR(A843) were expressed at equivalent levels (OD
values between four and ¢ve times that of control cells trans-
fected with the vector only).
4. Discussion
A current model for GPCR activation postulates a dynamic
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Fig. 4. Concentration-dependence for the Ca2 stimulation of phos-
phoinositide hydrolysis in transiently transfected HEK-293 cells ex-
pressing the wild-type, rho-C-hCaR and rho-C-hCaR(A843E)
cDNAs. Data are expressed as in the legend to Fig. 1.
Fig. 3. Intact cell ELISA for the quantitation of cell surface expres-
sion of wild-type and mutant hCaRs. The data are normalized as a
percentage of the value of the wild-type hCaR (set as 100%) using
HEK-293 cells transfected with vector alone as the negative control.
Each value represents the mean+S.E.M. of duplicate measurements
from four independent experiments.
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equilibrium between a conformation favoring G protein cou-
pling (R*) and one that does not favor G protein coupling
[17]. In the latter conformation, inhibitory constraints, includ-
ing possible interactions between key residues in several of the
transmembrane helices, prevent the spontaneous formation of
R*. In this model, agonist binding stabilizes the R* confor-
mation by somehow relieving the inhibitory constraints. For
GPCR in the rhodopsin subfamily in which agonists bind
directly within the seven transmembrane barrel, one can easily
imagine agonist-promoted alterations in interhelical interac-
tions that change the con¢guration of intracellular loops to
promote G protein coupling. For GPCRs such as the glyco-
protein hormone receptors and the CaR/mGluR subfamily
which have large ECDs that are believed to be the site of
agonist binding, how agonist binding leads to GPCR activa-
tion is far less clear.
Many naturally occurring, activating missense mutations
have been identi¢ed in various GPCR in a number of diseases
[1]. These missense mutations have provided an unique insight
into the mechanism of GPCR activation. Upon expression of
such mutated receptors, these have generally been shown to
cause an agonist-independent, constitutive activation leading
to the suggestion that mutation of the involved residues dis-
rupts the normal inhibitory constraints and allows the forma-
tion of R*. In contrast, activating CaR mutations have shown
an increased sensitivity to Ca2 rather than true constitutive
activation [3,6^8]. Of the 14 activating CaR mutations identi-
¢ed to date, nine are located in the ECD, a region suggested
to be important for Ca2 binding [18]. Missense mutations of
the ECD may therefore lead to an inappropriate CaR activa-
tion by increasing the a⁄nity for Ca2. However, even muta-
tions in the transmembrane domains of the CaR (F788C and
L773R in TM5, F806 in TM6) or in the ¢rst extracellular loop
(Q681H) have shown an enhanced sensitivity to Ca2 rather
than constitutive activation when expressed [7,10,16].
The A843E mutation in TM7 functionally characterized in
this paper is the ¢rst example of a CaR mutation causing a
constitutive activation rather than an enhanced Ca2 sensitiv-
ity. The A843 residue is conserved in human [19], bovine [18],
rat [20], chicken [21] and fugu [22] CaRs, as well as in the
closely related putative pheromone receptor, mv2R2 [23], con-
sistent with its functional importance. The comparable residue
is glycine, however, in the less closely related metabotropic
glutamate receptors (mGluR) [19]. We found that substitution
of glutamate for alanine 843 was required for constitutive
activation. Neither substitution of lysine or valine for alanine
843 nor glutamate substitution for the nearby and also highly
conserved alanine 840 led to a constitutive activation. Inter-
estingly, all three of these mutations, like A843E, lowered the
maximal Ca2 activation compared to wild-type CaR. Some
constitutively activating mutations of other GPCR have also
been associated with a reduced level of maximal agonist acti-
vation, e.g. the L457R mutation identi¢ed in TM3 of the LH
receptor in a subject with gonadotropin-independent preco-
cious puberty [24].
The unique e¡ects seen with the A843E mutation of the
CaR lead us to suggest, in keeping with the prevalent model
of GPCR activation, that this mutation, without Ca2 bind-
ing, disrupts the inhibitory constraints that prevent G protein
coupling. It is possible that the mutation leads to changes in
side chain packing in TM7 or in contacts with residues in
other TM helices. Such changes could alter the con¢guration
of one or more intracellular loops in such a way as to favor G
protein coupling. The inability to achieve a maximal activa-
tion to wild-type levels may signify that the mutation, while
promoting a conformation favouring G protein coupling, may
at the same time prevent the CaR from assuming the speci¢c
conformation most favorable for G protein coupling. Un-
fortunately, all of these possibilities must remain speculative
in the absence of a rigorously de¢ned structure for the CaR.
We were able, however, to test our hypothesis that the
A843E mutation activates the CaR by promoting G protein
coupling without requiring Ca2 binding to the ECD. By
attaching an N-terminal 20 amino acid segment of rhodopsin
to a CaR without the majority of the ECD (rho-C-hCar), we
were able to achieve high levels of cell surface expression. The
observation that rho-C-hCaR fails to respond to Ca2 is con-
sistent with the postulated role of the ECD in Ca2 binding
[18]. The fact that rho-C-hCaR is not constitutively activated
argues against a model of receptor activation in which the
ECD exerts a tonic inhibitory e¡ect through interaction
with the TM7 portion of the receptor, an inhibitory e¡ect
normally relieved by agonist binding to the ECD. Such a
model has been proposed for the TSH receptor, based in
part upon the ability of low concentrations of trypsin or of
certain ECD mutations to activate that receptor [25]. A direct
test of this model has not been done, since up to now a
truncated TSH receptor lacking the ECD has not been suc-
cessfully expressed in a form that reaches the plasma mem-
brane.
The A843E mutation, when expressed in the context of rho-
C-hCaR, still caused constitutive activation supporting the
idea that this mutation alters the conformation of the TM7
portion of the receptor in a manner independent of both Ca2
and the ECD. This still leaves open the question of how Ca2
binding and the ECD normally lead to receptor activation.
Based on the results seen with rho-C-hCaR, and by analogy
with the function of bacterial periplasmic binding proteins to
which the mGluR1 [26] and CaR [27] ECDs have been noted
to be homologous, we currently favor a model in which Ca2
binding causes a change in the conformation of the ECD that
promotes an interaction with the TM7 portion of the CaR.
This interaction alters helical interactions in a way that leads
to G protein coupling. Such a model would predict that there
may be other mutations of the TM7 portion of the receptor
such as A843E that will cause constitutive activation and that
there may also be residues in the postulated interface between
ECD and TM7 portions of the receptor which when mutated
will prevent receptor activation. Further studies to test this
model are underway.
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